ngm120
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 29, 2018 (NCT03392116)
Timeline
Indications
Studied for
- Cachexia · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Melanoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- GDNF family receptor alpha-likeINHIBITOR
GFRAL inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07033026 | Phase 2 | Jun 30, 2025 | NGM Biopharmaceuticals, Inc |
| NCT04068896 | Phase 1 | Aug 31, 2019 | NGM Biopharmaceuticals, Inc |
| NCT03392116 | Phase 1 | Jan 29, 2018 | NGM Biopharmaceuticals, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NGM Biopharmaceuticals, Inc | For profit | 3 | 3 | 2 | 2018 |
1 organizations
Page 1 / 1